With Spotlight On China, Regional Asian Opportunities Are Also Bright
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Rapid economic growth and the potential for the pharmaceutical industry in Asia go beyond China. A number of companies are boosting their regional presence, aware that focusing exclusively on Chinese growth may ignore the vast potential in other countries in Asia
You may also be interested in...
Bayer Shifting Further To Emerging Markets Including China
Already a big player in the world's largest pharmemerging market, China, Bayer is plunging deeper and reallocating more resources in capital investment and manpower to emerging markets
Bayer Shifting Further To Emerging Markets Including China
Already a big player in the world's largest pharmemerging market, China, Bayer is plunging deeper and reallocating more resources in capital investment and manpower to emerging markets
Novartis Tops Pfizer and GSK In South Korea's 2009 Insurance-covered Drug Sales
SEOUL - Novartis Korea edged Pfizer Korea and GlaxoSmithKline Korea last year to be the country's multinational pharma leader in sales for drugs covered by South Korea's national health insurance system